Anhedonia in Major Depressive Disorder: Understanding Patient Burden
The relationship of this key symptom of major depressive disorder and patient burden is not well understood. These two posters covered it.
Paliperidone Palmitate as a Treatment for Schizophrenia
These 3 posters covered the efficacy and safety of paliperidone palmitate in patients with schizophrenia.
Students Struggling With Suicide
The senior vice president of research at the American Foundation for Suicide Prevention offers thoughts on suicide and students.
Acknowledging International Overdose Awareness Day
Today is International Overdose Awareness Day!
Mental Health and Personal Finances Amongst Top Stressors for Students
A recent survey found mental health and finances were some of the top stressors for college students.
The Whole Continuum of Behavioral Health Care: Reintroduction of the 988 Implementation Act
The 988 Implementation Act was introduced on July 25. What impact will it have on care?
The Gut-Brain Connection: An Upcoming Study on Psilocybin-Assisted Psychotherapy and Irritable Bowel Syndrome
A phase 2A trial recently received confirmation to proceed in investigating psilocybin-assisted psychotherapy in the treatment of adult patients with IBS.
The Renaissance of Behavioral Health: 988 and Crisis Care
Learn more about a comprehensive system of care for those who are in crisis and need immediate access to care, aided by the new 988 Suicide & Crisis Lifeline.
Nasal Spray Demonstrates Ability to Reduce Social Anxiety Disorder Symptoms
Fasedienol meets trial endpoints by reducing anxiety during public speaking simulations in patients with social anxiety disorder.
The Rx Crisis: The Impact of Ongoing ADHD Medication Shortages
According to the National Community Pharmacists Association, 97% of independent pharmacy owners reported shortages of Adderall in early 2023. As these shortages continue, here's how you can best support your patients with ADHD.
Research Suggests Existence of Cognitive Biotype of Depression
A new cognitive biotype for depression may impact symptoms and treatment outcomes.
New Research, Treatment Issues Featured at Annual Meeting
Did you miss our APA Annual Meeting coverage?
Inside 988 Lifeline: Conversations with a Crisis Counselor
What is it like to be a 988 counselor?
A Year of 988: The First Step in a Long Journey
A year ago, the National Suicide Prevention Lifeline switched to its new 3-digit number, 988. What's happened since then?
Think Pink: Barbie & Unrealistic Body Expectations in 2023
Nearly 1 in 2 women compare themselves to Barbie.
Comorbid Depression and Anxiety Impacts Insomnia Treatment
New research finds depressive and anxiety symptoms impact effectiveness of cognitive behavioral therapy for insomnia.
Self-Medicating: More Than Half of At-Home Ketamine Users Misuse the Treatment
1 in 5 respondents reported using psychedelic drugs for the purpose of self-treating anxiety, depression, or other mental illnesses.
rTMS and Bipolar Depression: Predicting Clinical Response
Neuroimaging could help predict clinical response to treatment in bipolar depression.
Positive Data for Narcolepsy, Sleep Disorders, ADHD Drug
New positive data was recently released from 5 in vitro studies investigating the potential for drug-drug interaction of mazindol.
Understanding and Managing Behavioral and Psychological Symptoms of Dementia
Recognition is the first and most important step to treating behavioral and psychological symptoms of dementia.
Honoring Memorial Day: The Latest on the Military, Grief, and PTSD
In honor of Memorial Day...
“I Know It When I See It”: Definitions of Treatment-Resistant Depression
Presenters at the 2023 APA Annual Meeting compared definitions of treatment-resistant depression.
Categorizing the Jewish History of Resilience
Psychiatric Times’ very own H. Steven Moffic, MD, spoke about resilience and religion at the 2023 APA Annual Meeting.
Issues in the Military: A Conversation with Elspeth Ritchie, MD
Learn more about women’s issues, suicide, and PTSD in the military.
Tardive Dyskinesia, Huntington Disease Chorea Treatment Now Available
Deutetrabenazine extended-release tablets are now available.
Things To Do in San Francisco While You Are Visiting for the 2023 APA Annual Meeting
Here are some things to check out in the city while you're in town...
FDA Approves First Treatment for Agitation Associated With Alzheimer Disease Dementia
Brexpiprazole has been approved by the US Food and Drug Administration for the treatment of agitation associated with Alzheimer disease dementia.
NDA Approved for Long-Acting Injectable for Schizophrenia and Bipolar I
Aripiprazole will be the first 2-month LAI antipsychotic indicated for both the treatment of schizophrenia and the maintenance treatment of bipolar I disorder in the United States.
Phase 2/3 Study Begins for Generalized Anxiety Disorder Agent
Ulotaront, a trace amine-associated receptor 1 agonist with 5-HT1A agonist activity, is under investigation for the treatment of generalized anxiety disorder.
Positive Results for Lumateperone in Patients With Mixed Features in Major Depressive Disorder, Bipolar Depression
New results for a study evaluating lumateperone.
2 Clarke Drive Cranbury, NJ 08512